Innovent Biologics's revenue per share for the
six
months ended in Dec. 2023 was HK$2.42.
Innovent Biologics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4.35.
Warning Sign:
Innovent Biologics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Innovent Biologics was 27.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 9.00% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 124.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Innovent Biologics's Revenue per Share or its related term are showing as below:
HKSE:01801'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 9 Med: 216.75 Max: 451.7
Current: 9
During the past 8 years, Innovent Biologics's highest 3-Year average Revenue Per Share Growth Rate was 451.70% per year. The lowest was 9.00% per year. And the median was 216.75% per year.
HKSE:01801's 3-Year Revenue Growth Rate is ranked better than 58.61% of 778
companies
in the Biotechnology industry
Industry Median: 3.6
vs HKSE:01801: 9.00
Innovent Biologics Revenue per Share Historical Data
The historical data trend for Innovent Biologics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Revenue per Share
For the Biotechnology subindustry, Innovent Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's PS Ratio falls into.
Innovent Biologics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Innovent Biologics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Innovent Biologics Revenue per Share Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics (HKSE:01801) Business Description
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 